Begin main content

Reports

We found 4924 result(s)

Macitentan (Opsumit)

Last Updated: December 16, 2013
Result type: Reports
Product Line: Common Drug Review
Generic Name: Macitentan
Indications: Pulmonary arterial hypertension

  • Brand Name: Opsumit
  • Manufacturer: Actelion Pharmaceuticals Canada Inc.
  • Project Number: SR0364
  • Project Status: Complete
  • Submission Type: New

Dabigatran etexilate (Pradaxa)

Last Updated: March 18, 2013
Result type: Reports
Product Line: Common Drug Review
Generic Name: Dabigatran etexilate
Indications: Atrial fibrillation prevention of stroke and systemic embolism

  • Brand Name: Pradaxa
  • Manufacturer: Boehringer Ingelheim (Canada) Ltd
  • Project Number: SF0320-000
  • Project Status: Complete
  • Submission Type: RequestForAdvice

Tags

Atrial Fibrillation, Stroke, Stroke

Saxagliptin (Onglyza)

Last Updated: May 9, 2013
Result type: Reports
Product Line: Common Drug Review
Generic Name: Saxagliptin
Indications: Diabetes mellitus (Type 2)

  • Brand Name: Onglyza
  • Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.
  • Project Number: SR0329
  • Project Status: Complete
  • Submission Type: Pre-NOC

Somatropin (Genotropin)

Last Updated: May 27, 2013
Result type: Reports
Product Line: Common Drug Review
Generic Name: Somatropin
Indications: Growth hormone deficiency, adult

  • Brand Name: Genotropin
  • Manufacturer: Pfizer Canada Inc.
  • Project Number: SR0332
  • Project Status: Complete
  • Submission Type: New

Laquinimod for Relapsing-Remitting Multiple Sclerosis

Published on: March 31, 2014
Result type: Reports

Summary Laquinimod is a once daily, synthetic, oral immunomodulator currently under development for the treatment of relapsing-remitting multiple sclerosis (RRMS). Evidence of laquinimod’s efficacy in decreasing the rate of relapse in RRMS is inconsistent. Initial phase II and III placebo-controlled trials favoured laquinimod, but in a later pha...

  • Project Number: EH0010

Tags

Multiple Sclerosis, Nervous system, Multiple sclerosis

Remote Ischemic Conditioning for the Reduction of Ischemia-Reperfusion Injury in Acute Myocardial Infarction

Published on: February 5, 2015
Result type: Reports

Summary The autoRIC Device is a non-invasive device that provides automated delivery of remote ischemic conditioning (RIC), a temporary stop and restart of blood flow through a series of inflations and deflations of a blood pressure arm cuff. RIC is a novel adjunctive therapy for protection against ischemia-reperfusion injury in patients present...

  • Project Number: EH0020

Insulin Lispro: a critical evaluation

Published on: January 1, 1999
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Tags

Hypoglycemic Agents, Lispro, Diabetes Mellitus, Insulin Lispro, Diabetes, Mellitus, Non-Insulin-Dependent, Insulin-Dependent, Type 2 Diabetes, Type 1 Diabetes, Diabète non insulinodépendant, Diabète insulinodépendant, Hypoglycémiants, Chimiothérapie, Diabète de type II, Diabète de type I

Comparison of Drug Treatments for Multiple Sclerosis

Published on: January 1, 1998
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Cite as: Otten N. Comparison of drug treatments for multiple sclerosis. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1998. This rapid assessment brings together the major studies involving the four drugs available in various countries for the treatment of MS: Avonex® (interferon beta 1-a), Rebif® (interferon be...

Tags

Multiple Sclerosis, Interferon-beta, Peptides, Cost-Benefit Analysis, Treatment Outcome, Drug Therapy, beta-Interferon, Multiple sclerosis, Sclérose en plaques, MS, Economic, Interféron type I recombinant, Analyse coût bénéfice, Évaluation resultants traitement, Chimiothérapie, SEP, Interféron bêta-1b, Calcul des coûts

Coronary Stents: Clinical Experience and Cost-effectiveness

Published on: January 1, 1997
Result type: Reports

Cite as: Noorani HZ. Coronary stents: clinical experience and cost-effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997. Coronary stents are of value for the treatment of acute or threatened coronary artery closure complicating PTCA. Short-term clinical and angiographic outcomes are comparable with ...

Tags

Angioplasty, Stents, Coronary Disease, Cost-Benefit Analysis, Statistics, Heart Diseases, Transluminal Coronary Balloon Dilation, Angioplasty, Transluminal, Percutaneous Coronary, Cardiovascular, Medical devices, Transluminal, Percutaneous Coronary, Transluminal coronary balloon dilitation, PTCA, Heart disease, Economic, Angioplastie coronaire transluminale percutanée, Stent, Vaisseaux coronaries, maladies, Analyse coût bénéfice, Statistique, Angioplastie coronarienne transluminale percutanée, ACTP, Cardiopathie, Évaluation des coûts

CT and MRI for Selected Clinical Disorders: a Systematic Review of Clinical Systematic Reviews

Published on: October 21, 2005
Result type: Reports
Product Line: Health Technology Assessment, Technology Reports

Technology Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). Disease This report explores 13 conditions for which the use of CT and MRI remain controversial: arteriovenous malformations carotid artery disease, cerebral aneurysms, coronary artery disease, headaches, head injuries, lung cancer screening, peripheral vascular disease, p...

Tags

Review Literature, Magnetic Resonance Imaging, MR Tomography, fMRI, Magnetic Resonance Spectroscopy, MR Spectroscopy, NMR Spectroscopy, Nuclear Magnetic Resonance, Tomography, Meta-Analysis, Tomography, X-Ray Computed, MRI, CT scan, Revue de la littérature, systematic review, Systematic overview, Imagerie par résonance magnétique, MR Imaging, Spectroscopie résonance magnétique nucléaire, X-Ray Computed, Zonographie, tomographie, CT, Computed Tomography, CT Scanner, Méta-analyse, Meta analysis